ArticleMaterials today. Bio2025
Sequentially regulated immuno-osteogenic bioceramics enhance the regeneration of osteoporotic bone defects.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Advances in 3D bioprinting of immunoregulatory biomaterials for bone regeneration.Materials today. Bio · 2026Review
- FCRLB-mediated dual control of tumor metabolism and macrophage polarization promotes lung cancer malignancy.Journal of translational medicine · 2026Article
- Applications of Multifunctional Hydrogel in Tissue Engineering and Regenerative Medicine.MedComm · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sequentially regulating immune-osteogenesis to orderly transition from the inflammatory phase to bone reconstruction, and enhancing bone regeneration while inhibiting osteoclastic resorption, are crucial for the treatment of osteoporotic bone defect. Herein, the sequential loading and controlled release of interleukin-4 (IL-4) and alendronate (AL) based on the 3D-printed β-tricalcium phosphate (β-TCP) scaffolds were achieved via the Michael addition reaction combined with physical adsorption. IL-4 was rapidly released within two days, promoting M2 polarization of macrophage and secretion of anti-inflammatory and osteogenesis-associated factors. Meanwhile
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.